Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3269062 | PMC |
| http://dx.doi.org/10.5812/kowsar.1735143X.786 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effectiveness of 8-week Treatment with Glecaprevir/Pibrentasvir in Treatment-naïve or -experienced HCV Patients: Results from an Observational Retrospective Study in Real-life Settings (ODYSSEY).
J Gastrointestin Liver Dis
December 2024
Digestive Diseases and Liver Transplantation Center, Fundeni Clinical Institute, Bucharest, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.
Background And Aims: Pan-genotypic ribavirin-free oral direct-acting antivirals, including the glecaprevir/pibrentasvir combination, are recommended for the treatment of most patients with chronic hepatitis C virus (HCV) infection. In Romania, the HCV-infected patient population receiving glecaprevir/pibrentasvir is not well characterized and data on treatment effectiveness is lacking. The ODYSSEY study aimed to provide insights into the characteristics and treatment outcomes of HCV-infected Romanian patients receiving 8-week therapy with glecaprevir/pibrentasvir.
View Article and Find Full Text PDFCan antiviral drugs address the treatment challenges of severe fever with thrombocytopenia syndrome? - a systematic meta-analysis.
J Infect Dev Ctries
November 2024
Department of Administrative, Zhoushan Hospital, Zhoushan, China.
Background: Severe Fever with Thrombocytopenia Syndrome (SFTS) is an emerging infectious disease with high mortality and severity rates. However, there is no clear treatment plan, specific effective antiviral drugs, or effective vaccine for SFTS. Recent studies have shown that the therapeutic effect of Ribavirin and other commonly used antiviral drugs such as Favipiravir (T-705), on SFTS is still controversial.
View Article and Find Full Text PDFReal-World Experience, Effectiveness, and Safety of Direct-Acting Antivirals for the Treatment of Hepatitis C in Oman: A Cross-Sectional, Multicenter Study.
J Clin Med
December 2024
Department of Nursing, Sultan Qaboos University Hospital, University Medical City, Muscat 123, Oman.
: The advent of direct-acting antiviral (DAA) therapy has revolutionized the treatment landscape of the hepatitis C virus (HCV) infection. This study aimed to provide a comprehensive research study of the real-world effectiveness and safety of DAA treatment, representing the first study conducted in the Omani population. : A cross-sectional study was conducted including 375 HCV patients with different genotypes, treated using different DAA regimens, with or without ribavirin, between January 2012 and December 2020 at the Sultan Qaboos University Hospital and the medical city for military and security services, two tertiary hospitals in Muscat, Oman.
View Article and Find Full Text PDFFeline Adenovirus Isolate Shows Silent Nucleotide Alterations, Alternative Receptor/Coreceptor Binding, High Resistance to Disinfectants and Antiviral Drugs, as Well as Immunomodulation.
Animals (Basel)
December 2024
Department of Preventive Medicine and Public Health, Semmelweis University, 1085 Budapest, Hungary.
Adenovirus (AdV) infection has been rarely documented in cats and other felids. Partial sequences of the hexon and fiber genes of a Hungarian feline adenovirus isolate (FeAdV isolate) showed a close relationship to human AdV (HAdV) type C1. Further molecular and biological characterization is reported here.
View Article and Find Full Text PDFDengue (DENV) and Zika virus (ZIKV), transmitted by Aedes mosquitoes, pose significant public health challenges. Effective treatments for these viruses remain elusive, highlighting the urgent need for new efficient antiviral therapies. This study explores prodigiosin, a microbial tripyrrole pigment, as an antiviral agent against both DENV and ZIKV employing advanced analytical approaches which integrate molecular docking, CASTp 3.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!